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Introduction
In the last two decades, inactivated, live attenuated, replicationcompetent or -defective viruses have been extensively tested as viral vector-based vaccines. Interestingly, poxviruses such as Modified Vaccinia Ankara (MVA), New York strain of vaccinia virus (NYVAC), which are attenuated versions of vaccinia virus (VV), and Avipoxvirus; canarypox and fowlpox (FPV) viruses, used in prime-boost modalities have yielded uniquely different immune outcomes, dependent upon the route of delivery and/or the vaccine vector combination [1] [2] [3] [4] . For example, heterologous rFPV/rVV compared to rVV/rFPV vaccination has shown to induce highly poly-functional/ high avidity T cells [3, [5] [6] [7] , moreover, rMVA used as a booster, as opposed to a prime has shown to induce more effective T cell immunity [8] [9] [10] . Similarly, both replicationcompetent and -defective recombinant Adenovirus-based vaccines have also shown to induce T cell responses associated with immune protection in animal models [11] [12] [13] . Moreover, viruses such as, Influenza A, Human RV, Cytomegalovirus, and Vesicular stomatitis virus, have also been assessed as promising vaccine delivery vehicles [10, [14] [15] [16] . In a recent prime-boost vaccination study, mucosal RV prime vaccination was shown to induce HIVspecific T cell responses associated with protection in mice [17] . To improve vaccine-specific immunity, variants of viral vectors, such as IL-1bR and/or IL18 binding protein (IL-18bp) deletion mutants of MVA and Adenoviral vectors have also been recently tested [18] [19] [20] . Despite the knowledge of different viral vectorbased vaccines conferring different adaptive immune outcomes, the underlying innate immune mechanisms governing these processes at the vaccination site still remains elusive, specifically the role of innate lymphoid cells (ILCs) and dendritic cells (DCs).
ILCs, although derived from a common progenitor, are lineage negative in nature and according to the transcription factors, receptors and cytokines they express, are broadly classified into three main categories (ILC1, ILC2 and ILC3) [21] . ILC2, due to their ability to express IL-13, have been heavily studied under chronic inflammation, allergic asthma and helminth infections [22] . During intracellular pathogen infection, ILC1 have shown to express IFN-c and tumour necrosis factor (TNF)-a [23] , whilst during extracellular bacterial and fungal infections, ILC3 have been associated with interleukin (IL)-17A and IL-22 expression [24, 25] . Although ILCs have three distinct phenotypes, studies have shown that they have the ability to interconvert between the phenotypes, according to the external stimuli, and thus thought to be highly plastic [26, 27] . It is postulated that ILCs can polarize the immune response, according to the immune cell milieu or pathogen encountered, towards Th1, Th2 or Th17 immunity. However, the role of ILCs in viral vector-based vaccination is not well characterised.
DCs sample antigens at various body surfaces; skin, gastrointestinal tract and lungs, and are among the first line of defence against many pathogens. Based on the anatomical location and the invading pathogen, distinct DC subsets carry out differential functions [28] . For example; lung DCs have been extensively studied under respiratory infections. Lung conventional CD11b +
CD103
À DCs (cDCs) and cross-presenting CD11b À CD103 + DCs have been associated with CD8 T cell priming [29, 30] . Although conflicting evidence suggest that cDCs are functionally more important in mounting an effective antiviral response [31, 32] , there is growing evidence to support the notion that the activity of a particular DC subset is determined by the specific infection. For example: control of acute influenza virus infection is associated with CD11b À CD103 + DCs cross presentation to CD8 T cells [33] , whilst, CD11b À CD8 + DCs, which share a common developmental origin with CD11b À CD103 + DCs, have been associated with activation of cytotoxic CD8 T cells against non-respiratory pathogens such as West Nile Virus [34] . In the context of respiratory syncytial virus (RSV) infection, CD11b + and CD103 + DC subsets have been involved in antigen presentation to both CD4 and CD8 T cells [35] . In addition, during Influenza A infection, CD11b + DCs have also been associated with humoral immunity [36] . Furthermore, plasmacytoid DCs (pDCs) also have been associated with distinct functions during viral infections [37, 38] . It is now well established that the route of delivery, cytokine milieu, viral vectors and the order in which they are administered can yield vastly different adaptive immune outcomes [3, 5, 7, 39, 40] . We have previously shown that (i) IL-13, although detrimental for high avidity/poly-functional CD8 T cell immunity, was necessary for effective antibody differentiation [41] [42] [43] . (ii) Using rFPV adjuvanted vaccines that transiently inhibited IL-13 activity at the vaccination site, we have recently established that ILC2 (not other lineage + cells) were the major source of IL-13 at the vaccination site 24 h post vaccination [44] . (iii) Furthermore, using the same vaccines we have also shown that elevated IL-13 in the milieu recruited CD11b À CD103 + cross-presenting DCs, associated with low avidity CD8 T cells [42, 45] . Therefore, in this study to further understand which specific innate immune cell subsets play a predominant role in shaping the downstream adaptive immune outcomes, replicating and non-replicating viral vectors were delivered intranasally and intramuscularly and subsequent ILCderived cytokine profiles and DCs subsets were assessed 24 h post vaccination. 1A and S3 ). However, despite this, RV and Ad5 expressed elevated IL-13 levels, which were similar to rMVA and Influenza A (Fig. 1B) . Among the three poxviral vectors tested, the highest IL-13 level was detected in rMVA (rFPV vs rMVA p < 0.0001, rMVADIL-1bR vs rMVA p < 0.0001), whilst rMVADIL-1bR showed the lowest (rFPV vs rMVADIL-1bR p = 0.4159) (Fig. 1B) . It is also noteworthy that, all the vectors showed significantly elevated IL-13 expression by Lin À ST2/IL-33R + ILC2 compared to the unimmunized control (rFPV p = 0.0028; rMVA p < 0.0001; rMVADIL-1bR p = 0.0412; Influenza A p < 0.0001; RV p < 0.0001; Ad5 p < 0.0001) (Fig. 1A and B ) were found to express marginal IL-13. In contrast, compared to the unimmunised control, a not yet defined ILC2 subset that lacked IL-25R, ST2/IL-33R and TSLPR were found to express IL-13 ( Fig. 1E and F) . Out of the vectors tested, Ad5 showed remarkably higher proportion (2 to 3-fold) of IL-25R
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À IL-33R À TSLPR À cells expressing IL-13 (p < 0.0001) ( Fig. 1E and F) , which was comparatively lower than i.n. Ad5 vaccination (Fig. 1B) . It is noteworthy that, the ILC2-derived IL-13 expression by each vector was significantly higher following i.m. delivery compared to i.n. delivery. (Note that: The parent ILC2 population in the i.m. groups were much greater than the i.n. ST2
+/ IL-33R + ILC2s. Thus, the difference in IL-13 expression by these two ILC subsets were also represented normalised to the CD45 + subset, described in materials and methods (Fig. 1J ). lowed by Ad5 (average 5%) and rFPV (average 2.9%) (Fig. 2B ).
Unlike rFPV, the deletion mutant rMVADIL-1bR and rMVA showed significantly lower IFN-c expression (p = 0.0187, and 0.0011 respectively), which was also lower than the unimmunized control (p = 0.0086 respectively) (Fig. 2B) . Expression of IFN-c by Influenza A was similar to that of the unimmunized control. Interestingly, following i.n. delivery 95-98% ILC1/ILC3s were found to be NKp46 À ( Fig control showed elevated NKp46 À ILC1/ILC3 numbers, low or no expression of IFN-c was observed (Fig. 2D , E and S3). Remarkably, rMVADIL-1bR induced the highest IL-17A expression by both NKp46 + ( Fig. 2C ) and NKp46 À ILC1/ILC3 subsets (Fig. 2F) . rMVA and Influenza A vectors induced modest IL-17A expression by both these subsets, whilst rFPV, Ad5 and RV showed no IL-17A expression, similar to the unimmunized control ( Fig. 2C and F) . Unlike i.n., following i.m. delivery, the proportion of NKp46 + ILC1/ILC3 in the muscle was very minimal (0-0.8%) across all vaccine vectors ( Fig. 2A and Fig. 3A) , with significant differences observed between rMVA compared to rFPV, rMVADIL-1bR and Ad5 (p = 0.0087p = 0.0049, and p = 0.0397 respectively). Additionally, only rFPV and Influenza A vaccinated groups showed any expression of IFN-c by NKp46 + ILC1/ILC3 (Fig. 3B) . Interestingly, IFN-c expression by these subsets was much greater following i. m versus i.n. vaccination (rFPV i.m. $12.06% i.n. 2.5% and influenza A i.m. $ 4.67% i.n. $1.5%) (Fig. 2B and Fig. 3B ). In the context of IL-17A expression by NKp46 + ILC1/ILC3, only Influenza A vaccinated animals showed any significant expression (average 8.39%, p < 0.0001 influenza A vs. all vaccine vectors) (Fig. 3C) . Of the poxviral vectors tested, rMVADIL-1bR vaccinated group also showed an increase in the proportion of NKp46 + ILC1/ILC3 expressing IL-17A (average 0.89%) although not significant and was similar to what was observed with i.n. delivery (average 1.0%). Moreover, following i.m. delivery, different IFN-c and IL-17A expression profiles were detected by NKp46 À ILC1/ILC3. Unlike i.
n. delivery, very low IFN-c expression was detected following i. m. vaccination, and only influenza A ($0.01%) and Ad5 ($0.03%) showed any IFN-c expression (Fig. 2E and Fig. 3E ). All vectors showed different NKp46 À ILC1/ILC3-derived IL-17A expression profiles. Specifically, out of the vectors tested, Ad5 and rMVADIL1bR showed the highest expression ($0.58% and $0.84% respectively) (Fig. 3F) . Interestingly, the NKp46 À ILC1/ILC3-derived IL-17A expression by the rMVADIL-1bR group was significantly elevated compared to unimmunised, rFPV, rMVA and influenza A (p < 0.0001, p = 0.0064, p < 0.0001, and p < 0.0001 respectively) (Fig. S4) . Whilst, Ad5 showed significant differences compared to unimmunised, rMVA, and influenza A vaccinated groups (p = 0.0048, p = 0.0172 and p = 0.0219 respectively) (Fig. S4 ). 
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À cDCs compared to rMVA and rVV (p = 0.0062, p = 0.0322 respectively). Additionally, the deletion mutant rMVADIL-1bR recruited the highest percentage of CD11b + CD103 À cDCs, whilst Ad5 recruited the lowest (Fig. 4A and B) . Furthermore, CD11b + CD103 À cDC recruitment by Influenza A was similar to that of rFPV, rMVA, rVV and RV ( Fig. 4A and B) . Compared to the unimmunized control, rFPV, rMVADIL-1bR and Influenza A showed significant elevated CD11b + CD103 À cDC recruitment (p = 0.0069, p < 0.0001 and p = 0.0077 respectively). that of the unimmunized control (p = 0.0224), and these values were significantly lower than that of rVV, Influenza A and RV vectors (p < 0.0001, p = 0.0065 and p < 0.0001 respectively) ( Fig. 4A  and C) . Interestingly, compared to all viral vectors tested, rVV recruited the highest percentage of CD11b À CD103 + crosspresenting DCs to the lung mucosae 24 h post vaccination. Whilst, rFPV recruited the lowest number similar to rMVA, rMVADIL-1bR and Ad5 (Fig. 4C) . Furthermore, the proportion of CD11b À CD8 + cross-presenting DCs recruited by all the vaccine vectors showed a comparable profile to that of the CD11b À CD103 + crosspresenting DCs, where rVV showed the highest proportion of CD11b À CD8 + cross-presenting DCs (Fig. 5A and C) . It is noteworthy that the cross-presenting CD11b À CD103 + DCs recruited by rVV, Influenza A and RV were significantly higher than unimmunized control (p < 0.0001, p = 0.0067 and p = 0.0113 respectively) ( Fig. 4A and C) . Whereas, cross-presenting CD11b À CD8 + DCs recruited by rVV and Influenza A although were significantly higher than unimmunized control (p < 0.0001, p = 0.0498 respectively), Ad5 recruitment was significantly lower (p = 0.0164) ( Fig. 5A and C) . Next when the CD11b À B220 + pDC recruitment profile was assessed, these DCs showed a unique profile compared to the other three DC subsets examined. At 24 h post vaccination, RV and Ad5 recruited the highest percentage of CD11b À B220 + pDCs to the lung mucosae, whilst Influenza A, rFPV and rMVADIL-1bR showed the lowest ( Fig. 5B and D) . Among the poxviral vectors, rVV recruited the highest proportion of CD11b À B220 + pDCs whilst rFPV recruited the lowest, and rMVA and rMVADIL-1bR showed a similar pDC profile. Compared to the unimmunised control, rVV, RV and Ad5 vectors showed significant differences in pDC recruitment 24 h post vaccination (p = 0.0025, p < 0.0001 and p < 0.0001 respectively) (Fig. 5B and D) .
Intranasal rVV vaccination recruited elevated numbers of CD11b
Following intranasal vaccination different viral vectors showed different kinetic profiles 0 to 48 h post vaccination
Next, we also evaluated the DC recruitment kinetics 0 to 48 h post vaccination. Distinct DC kinetic profiles for each of the vectors were detected over time. rFPV showed significant regulation of CD11b + CD103 À cDCs, which was similar to the cDC profile induced by the rMVA deletion variant (rMVADIL-1bR), unlike the parental rMVA ( Fig. 6A and S6 ). The replication competent rVV showed regulation of all DC subsets, with significant modulation of crosspresenting DCs. Interestingly, cDC recruitment kinetics between rVV, rMVA and Influenza were very similar ( Fig. 6B and S6 ). Ad5 recruited a pDC profile similar to RV and a CD11b À CD8 + profile similar to rVV (Fig. 6B, C and S6 ).
Discussion
This study has clearly demonstrated that not only the route of vaccination, but also different viral vector-based vaccines can induce significantly different ILC subsets at the respective vaccination sites 24 h post delivery. In agreement with our current study, i.n. Ad5 vaccination has also shown comparable ILC2 gene expression profiles to i.n. rFPV, unlike i.m. Ad5 delivery (Jaeson et al. submitted). Taken together, these findings may explain why systemic vaccination with some viral vectors may lead to suboptimal antiviral immunity, compared to mucosal vaccination [6, 7, 52, 53] .
Besides the route of delivery, each viral vector also induced a uniquely different ILC2-driven IL-13 and ILC1/ILC3-driven IFN-c expression profiles. Specifically, both i.n. and i.m. rFPV vaccination induced low ILC2-derived IL-13, and high NKp46 + or NKp46 À ILC1/ ILC3-derived IFN-c. In contrast, i.m. rMVA vaccination induced lower ILC2-derived IL-13 compared to i.n. delivery. Knowing that, low IL-13 is associated with improved T cell immunity, our current data may explain why previously rMVA has been found to be more efficacious as an i.m. delivery vector than a mucosal delivery vector [8, 10] . Moreover, whilst i.n. delivery of rMVA, Influenza A, RV and Ad5 induced elevated ILC2-derived IL-13, the expression of IFN-c was lower in NKp46 + ILC1/ILC3s following rMVA, Influenza A; In asthma studies the importance of maintaining IL-13 and IL-17 balance has been well documented [54] . Similarly, our vaccination studies have also shown that IL-13 can regulate IL-17A expression on T cells at the transcriptional and translational level, and IL-17A is associated with T cell mediated protective immunity [55] . Knowing that (i) rVV and its derivatives (rMVA) perform better as a booster vaccine than a prime [7, 8] (ii) Influenza A prime yield poor adaptive immune outcomes (Tan, Derose et al. personal communication) [51] and (iii) systemic Ad5 immunization have shown to induce less effective antiviral T cell responses [12, [56] [57] [58] , collectively our data suggest that the early onset of high ILC1/ILC3-derived IL-17A together with low IFN-c and high ILC2-derived IL-13 could be detrimental for inducing effective cellular immunity. Our study demonstrated that in addition to different ILC profiles, mucosal vaccination with different viral vectors yielded uniquely different lung DC profiles at the vaccination site 24 h post vaccination. We have previously shown that IL-13 levels at the vaccination site can significantly alter DC phenotype, specifically, inhibition of IL-13 can recruit elevated CD11b + CD103 À cDCs associated with high avidity T cells [45] . This study further substantiated our previous findings of enhanced recruitment of CD11b + CD103 À cDCs as opposed to CD11b À CD103 + crosspresenting DCs following i.n. rFPV vaccination. Moreover, moderate proportions of CD11b À B220 + pDCs were also observed with rFPV vaccination. pDCs are known to induce antibody differentiation via IFN-c production [40] and their clustering with cDCs have shown to induce efficient T cell mediated antiviral immunity [38] . We have already established that rFPV priming can induce robust high avidity T cells and differentiated antibodies, involved in protective immunity against viral pathogens such as HIV [7, 41] . Thus, our current findings suggest that although in the context of certain viral vectors, the cDC/pDC balance may govern the quality of T and Error bars represent SEM and p values were calculated using One-way ANOVA followed by Tukey's multiple comparison test (black lines) and paired student's t test (grey lines). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Experiments with each vector were repeated minimum 2-3 times.
B cell immunity, replicating vectors such as Influenza A may employ other mechanisms (as Influenza A showed similar cDC/ pDC profile to rFPV associated with poor quality T cells). In contrast to rFPV vaccination, rMVA lead to elevated ILC2-derived IL-13, similar to rVV (data not shown), and both vectors significantly enhanced recruitment of CD11b À CD103 + crosspresenting DCs to the lung mucosae, as shown previously [45] . This may explain why rMVA and rVV priming lead to low avidity T cells following recombinant HIV vaccination [3, 7] . Moreover, intranasal Influenza A, RV and Ad5 vaccination which also lead to high ILC2-derived IL-13, preferentially induced CD11b À CD103 + crosspresenting DCs as opposed to cDCs. In a prime-boost vaccine modality, recombinant Influenza A priming has shown to induce enhanced magnitude of vaccine-specific T cells, however, are of low avidity unlike rFPV priming (Tan, Derose et al. personal communication). Similarly, recombinant Ad5 vaccination has also shown to induce high magnitude of vaccine-specific CD8 T cells [13] . Therefore, these observations suggest that these vectors although lead to enhanced magnitude of vaccine-specific T cell immunity (IFN-c production by T cells), may lead to low avidity T cells against chronic infections such as HIV- DCs, could also be associated with induction of low avidity T cells.
However, in the context of some pathogens, (for example, Leishmania, and also some viruses, Infleunza and HSV-1 infections), induction of cross-presenting DCs have been associated with protective immunity [30, 59, 60] . Thus, when designing recombinant viral vector-based vaccines, careful selection of the vector, according to the pathogen of interest may be of great importance. rMVADIL-1bR is known to induce effective memory T cell responses compared to parental rMVA vaccination [61] . Unlike rMVA, rMVADIL-1bR induced low ILC2-derived IL-13 and elevated cDCs similar to rFPV, which has shown to induce high avidity T cells with better protective immunity. These findings indicated that removal of a single immune evasive gene from the viral vector can significantly alter the innate immune outcomes, specifically the ILCs and DCs, associated with effective protective immunity. However, compared to rFPV (which showed elevated IFN-c and no IL-17A expression), rMVADIL-1bR vaccination induced suboptimal ILC1/ILC3-derived IFN-c and high IL-17A expression at the vaccination site. It is well established that IFN-c is crucial for antiviral immunity, and overexpression of IL-17A can lead to immune imbalance [62] . It is also known that viral IL-18 bp neutralize host IL-18 and prevent IFN-c production [63] . Thus, the residual IL-18 bp in the rMVADIL-1bR vector could be responsible for the observed ILC1/ILC3-derived IFN-c profile. Thus, we postulate that rMVA vector lacking both IL-1bR and IL-18 bp genes may lead to ILC/DC profiles similar to rFPV and balanced T and B cell outcomes.
Furthermore, rVV, rMVA and rMVADIL-1bR data clearly demonstrated that the attenuation status of a viral vector and the presence or absence of virokines significantly modulated the ILC cytokine expression and DC profile. The rFPV and rMVADIL-1bR data indicated that viral vectors that do not interfere with the host immune system could be more efficacious at inducing vaccinespecific immunity in humans (e.g.-Avipoxvirus compared to Orthopoxvirus). These observations strongly highlight the notion that when designing viral vector-based vaccines, in addition to the safety and genetic stability, inherent properties of the viruses themselves need serious consideration (in this case, its replicative ability within the mammalian host).
We have previously shown that ILC2s are the only source of IL-13 at the vaccination site, 24 h post vaccination and IL-13 level in the milieu can crucially impact the DC recruitment at the lung mucosae [42, 44, 45] . Hence, collectively our findings suggest that, early ILC2-derived IL-13, together with ILC1/ILC3-derived IFN-c and IL-17A, differentially impact DC recruitment/regulation at the vaccination site, associated with adaptive immune outcomes and this warrants further investigation. Therefore, we postulate that (i) following vaccination, ILC and DC profiles may act as predictors of downstream vaccine-specific immunity and (ii) selection of viral vector according to the pathogen of interest (eg: virus, bacteria or parasites) may help tailor/design effective viral-vector based vaccines against chronic pathogens.
Materials and Methods
Mice. Pathogen-free 6-8 weeks old female BALB/c mice were purchased from the Australian Phenomics Facility, The Australian National University. All animals were maintained, monitored daily and cervically dislocated at the endpoint according to the Australian NHMRC guidelines within the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and in accordance with guidelines approved by the ANU Animal Experimentation and Ethics Committee (AEEC), protocol number A2014/14 and A2017/15.
Viral vector-based Vaccines. Recombinant FPV, VV and MVA expressing HIV antigens described previously were used in this study [44, 64] . The rMVADIL-1bR was constructed and kindly provided by Dr. Jackson. Influenza A and Adenovirus (Ad5) vectors were kindly provided by Prof. Arno Mullbacher, JCSMR, ANU. Recombinant Human Rhinovirus serotype 1A (RV) was kindly provided by Prof. Gowans and Dr. Wijesundara, Basil Hetzel Institute, University of Adelaide [16] .
Immunisation. BALB/c mice were intranasally or intramuscularly immunised with 1x10 7 plaque forming units (pfu) of each of the poxviruses rFPV, rVV, rMVA, rMVA-DIL-1bR; 2x10 7 pfu (i.
n.) or 2.5x10 7 pfu (i.m.) of Ad5, 5 Â 10 6 TCID 50 of RV or 500 pfu of Influenza A. Note that, doses used were comparable to those used in previous studies, optimal to induce adaptive immune outcomes. Mice were vaccinated with 10 mL per nostril (i.n.) or 50 lL per leg (i.m.) under mild isofluorane anaesthetic. rFPV, rVV, rMVA, rMVA-DIL-1bR were sonicated three times for 15 s on ice at 50% capacity using Branson Sonifier 450 immediately prior to vaccination. Preparation of lung lymphocytes. Lung tissues were collected 24 h post vaccination in complete RPMI for ILC studies as described previously [44] . For DC studies, lungs were harvested at 12, 24 and 48 h post vaccination. Lung tissues were prepared as described previously [44] . Briefly, tissues were cut into small pieces, and enzymatically digested for 45 min at 37°C in digestion buffer containing 1 mg/ml collagenase (Sigma-Aldrich, St Louis, MO), 1.2 mg/ ml Dispase (Gibco, Auckland, NZ), 5 Units/ml DNase (Calbiochem, La Jolla, CA) in complete RPMI. Samples were crushed and passed through a 100 mm falcon cell strainer and resulting lung cell suspensions were then treated with red cell lysis buffer followed by extensive washing to remove the lysis buffer. Samples were then passed through gauze to remove debris, cells were re-suspended in complete RPMI, rested overnight at 37°C under 5% CO 2 as per our previous studies prior to staining [5, 42] .
Preparation of muscle lymphocytes. Muscle tissues were harvested 24 h post vaccination in complete RPMI and prepared as previously indicated [44] . Briefly, tissues were, homogenised and enzymatically digested for 45 min at 37°C in a digestion buffer containing 2 mg/mL collagenase, 2.4 mg/mL dispase and 5 Units/ mL of DNAse in complete RPMI. Subsequently, samples were very gently pushed through a 70 lM Falcon cell strainer, to avoid debris.
Resulting cell suspension was then washed, resuspended in complete RPMI and rested overnight as per lung prior to staining [5, 42] Evaluation of lung and muscle ILCs using flow cytometry. 2), Alexa Fluor 700-conjugated IL-17A (clone TC11-18H10.1) were obtained from BioLegend. PEeFluor 610-conjugated anti-mouse IL-13 (clone eBio13A) was purchased from eBioscience and APC-conjugated anti-mouse TSLPR R&D systems. ILC2 and ILC1/3s were stained separately to avoid fluorochrome overlap. Specifically, FITC-conjugated lineage cocktail antibodies and APC/Cy7-conjugated anti-mouse CD45 were used in both ILC2 and ILC1/ILC3 staining. For lung and muscle ILC2 staining, PE-conjugated anti-mouse ST2/IL-33R, and PEeFluor 610-conjugated anti-mouse IL-13 were used and for muscle ILC2 staining, additionally APC-conjugated IL-25R and APCconjugated anti-mouse TSLPR were used. Brilliant Violet 421-conjugated anti-mouse NKp46, Brilliant Violet 510-conjugated anti-mouse IFN-c, Alexa Fluor 700-conjugated IL-17A were only used in ILC1/3s staining. Briefly, for intracellular staining, samples were treated with Brefeldin A for 5 h, washed, cell surface staining was performed followed by and intracellular staining after fixing and permeabilising the cells as per our previous protocols [42] . Once the staining was completed all samples were fixed with 0.5% paraformaldehyde, 1.4 Â 10 6 events from each lung sample were acquired and 3.0 Â 10 6 events were acquired for muscle on a BD LSR Fortessa. Data were analysed using Tree Star FlowJo software (version 10.0.7) using gating strategies indicated in Figs. S1 and S2. Evaluation of lung DCs using Flow cytometry. 2 Â 10 6 cells were blocked with anti-mouse CD16/CD32 Fc Block antibody (BD Biosciences, USA) for 20 min at 4°C and cells were surface stained with APC conjugated MHCII I-Ad (e-Biosciences, USA), biotin conjugated CD11c (N418 clone, Biolegend, USA), followed by streptavidin Brilliant violet 421 (Biolegend, USA) and other DC markers CD8 APC-eFluor780 (53-6.7 clone, ebiosciences, USA), B220 PercpCy5.5 (RA3-6B2 clone, e-Biosciences, USA), CD11b AlexaFluor 700 (M1170 clone, Biolegend, USA) and CD103 FITC (2E7 clone, eBiosciences, USA) for 30 min on ice. Cells were resuspended in PBS and analysed using BD LSRII flow cytometer Becton Dickinson, San Diego, CA). 5 Â 10 5 events per sample were collected and results were analyzed using FlowJo software version 10.0.7, as described in Fig. S2 . Note that, live/dead staining was also performed using viability dye 7-amino-actinomycin D (7-AAD Biolegend, USA) (Figs. S2A and S2B ). Statistical analysis. Cytokine expression by ILCs was calculated as a percentage of the parent ILC subset. To depict the differences in IL-13 expression, following i.n. vs i.m. vaccinations, number of ILC2 expressing IL-13 were also back calculated to CD45 + population and normalized to 1 Â 10 6 . The muscle ILC2 subset percent-ages were calculated as (subset of interest/Lin À population Â 100%). The DC subsets were represented as a percentage of total MHC-II + CD11c + DCs. The p-values were calculated using two-tailed paired parametric student's t-test, unpaired parametric student's t-test or Ordinary One-way ANOVA with Tukey's multiple comparison post-test. All experiments were repeated minimum 2-3 times.
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